Experience
Novartis Pharmaceuticals Corporation et al.
Fresenius Kabi USA, LLC et al.
Represent Novartis in district court litigation against multiple generics related to KISQALI ®, a blockbuster, breakthrough CDK4/6-inhibitor for the treatment of breast cancer.
Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al., 1:21-cv-00870, D. Del., Judge Hall
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
Novartis Gene Therapies, Inc. et al.
Real Time Social Inventions LLC v. Conduit USA, Inc. et al.
Conduit USA, Inc. et al.
Biogen Int’l GmbH v. Amneal Pharmaceuticals LLC et al.
Biogen Int’l GmbH
Salient Systems Corporation v. Hawk Technology Systems LLC et al.
Salient Systems Corporation
Abbott Laboratories v. Teva Pharmaceuticals USA, Inc.
Abbott Laboratories
Zimmer Surgical, Inc. et al. v. Stryker Corporation et al.
Zimmer Surgical, Inc.
Eidos Display, LLC et al. v. AU Optronics Corporation et al.
HannStar Display Corporation and Hannspree North America, Inc.
BioDelivery Sciences International, Inc. et al. v. Alvogen PB Research & Development LLC et al.
BioDelivery Sciences International, Inc. et al.
Uniloc USA, Inc. et al. v. Motorola Mobility LLC et al.
Motorola Mobility LLC et al.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.